Langjierui Biotech

朗捷睿

Langjierui Biotech

Biotech/Healthcare

Founded on December 28, 2020, Langjierui develops novel metabolic checkpoint modulators. Its pipeline focuses on innovative drugs for major chronic diseases closely associated with metabolic checkpoints, including cancer, autoimmune diseases, neurodegenerative diseases, polyarteritis, phlebitis…

Latest round: Series A (2026)

Source: ChinaBulls — chinabulls.com

Last updated 2026-06-01